Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis

Aggregated risk of carbamazepine (CBZ)‐induced cutaneous adverse drug reactions (cADRs) with different HLA variants are unclear and limited in terms of the power of studies. This study aimed to assess the aggregated risk of CBZ‐induced cADRs associated with carrying the following HLA variants: HLA‐B...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational science 2022-08, Vol.15 (8), p.1887-1905
Main Authors: Biswas, Mohitosh, Ershadian, Maliheh, Shobana, John, Nguyen, Ai‐Hoc, Sukasem, Chonlaphat
Format: Article
Language:English
Subjects:
Alleles
Analysis
Anticonvulsants - adverse effects
Antigens
Benzodiazepines
Carbamazepine
Carbamazepine - adverse effects
Genetic diversity
Genetic Predisposition to Disease
Genotype
Histocompatibility antigen HLA
HLA-A Antigens - genetics
HLA-B Antigens - genetics
Humans
Meta-analysis
Software
Systematic review
Toxic epidermal necrolysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aggregated risk of carbamazepine (CBZ)‐induced cutaneous adverse drug reactions (cADRs) with different HLA variants are unclear and limited in terms of the power of studies. This study aimed to assess the aggregated risk of CBZ‐induced cADRs associated with carrying the following HLA variants: HLA‐B*15:02, HLA‐B*15:11, HLA‐B*15:21, HLA‐B*38:02, HLA‐B*40:01, HLA‐B*46:01, HLA‐B*58:01, HLA‐A*24:02, and HLA‐A*31:01. Literature was searched in different databases following PRISMA guidelines. The outcomes were measured as odds ratio (OR) using RevMan software by a random/fixed effects model, where p 
ISSN:1752-8054
1752-8062
1752-8062
DOI:10.1111/cts.13291